IndusInd Bank posted Q1FY14 numbers above analyst expectations. Net Profit registered 42 percent yearon-year growth to touch Rs. 335 crore (as compared to street expectation of 34 percent growth in bottom line. Strong growth in other income helped by treasury gains and net interest income (NII) helped the Bank to post robust performance. NII was seen going up by 41 percent to Rs. 682 crore in the first quarter. During the quarter, other income surged 48 percent y-o-y to Rs. 471 crore while NII increased 40 percent to Rs 680 crore. Other income has increased owing to significant gains in treasury income. The Bank's treasury income has witnessed qoq growth of whopping 486 percent to touch Rs. 104.5 crores. Foreign exchange income also witnessed qoq growth of 26 percent to Rs. 92 crores in Q1FY14.The bank expanded its loan book by 27 percent to Rs. 47,425 crore. The recent promotional campaign of the Bank...
The Company is among the leading textiles companies in India with presence in PV (polyester viscose) dyed yarn and fabrics. It is the largest producer of PV dyed yarn in Asia at a single location with 25 percent market share in India. The Company is the largest player in Indian dyed PV yarn with around 35 mn kgs annual production. Engaged in the manufacturing of woven fabrics which are mainly used for suits and trousers and are sold in the domestic market. It is a fully integrated player from yarn to branded garments. The Company has manufacturing facilities at Biliya - Bhilwara, Sareri Bhilwara and Atun Bhilwara. The textile business has picked pace on favourable government policies to cotton price stabilization and demand push for the apparel sector. With the completion of the Denim expansion, the...
Sun Pharma is an international, integrated, speciality pharmaceutical company with brands and branded generics in US, India and over forty markets across the world. A comprehensive product offering with technology-based differentiation are a highlight of the portfolio. Sun Pharma is the largest specialty pharmaceutical company in India with established brands across niche therapies such as psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. In the United States of America, Sun Pharma is an integrated generic drugs company with several complex products approved for sale. Sun Pharma's API (Active Pharmaceutical Ingredients) program began in 1995 to facilitate the manufacture of complex formulations and products for which complete vertical integration would help the business. APIs are currently manufactured at nine plants, including locations in Hungary, US and Israel. Technical capabilities and dedicated sites to make complex API such as anticancers, peptides, sex hormones...
India's second-largest sanitaryware major with a marketshare of 23%, competes with leader Hindustan Sanitaryware & Industries (41% share). High marketing spends have ensured good brand visibility with sales clocking a CAGR of 28% and profits doing over 34% in the past five years. Over 55% of its products are produced in-house. That demand has been robust is evident from the 53% revenue growth Cera clocked in FY13 with operating margins of 15.4%, despite higher raw material costs. It is now foraying into the tiles...
Eros Worldwide FZ LLC (the "Sellers") has submitted to BSE a Notice of Offer for Sale of an aggregate of 25,73,710 equity shares of Rs. 10 each of Eros International Media Ltd (the "Sale Shares") representing 2.8% of the equity share capital of the Company, by Promoter (the "Sellers") through a...
Non Betallactum to drive API business growth: The Company expects the Semi Synthetic Penicillin and Cephalosporin API business to grow by 10%. A major chunk of the API segment growth will come from non betallactum APIs which have grown by 71.3% in Q1FY13. Management has guided for close to 50% and 30% sales growth for non betallactum APIs in FY13E and FY14E, respectively. Semi Synthetic Penicillin and Cephalosporin sterile APIs have been affected due to ban on Unit VI. USFDA inspecvtion of injectibles facility a silver lining: The company's Unit VI and IV facilities were recently inspected by the USFDA. We expect both the facilities to...
Since 1851, the name Singer has been synonymous with sewing. The spirit of practical design and creative innovation that characterized the Company at its beginning continues today as the companies develop products for every level of sewing. The Company has celebrated many firsts, including the world's first Zig-Zag machine the Fashion Maker. The Company has been on a restructuring spree. SIL has turnaround smartly and has wiped off its losses worth Rs. 6.46 crores as on 30th June 2011. With the successful implementation of the restructuring scheme, the Company's Reserves and Surplus have turned positive at Rs. 3.76 crores as on 30th June, 2012. The Company reported a net profit...
United Phosphorous created a number of agro-management products comprising seed, preharvest and post harvest products. The company has 21 manufacturing facilities. Among them, 9 are in India, 4 are in France, 2 in Spain and one each in UK, Argentina, Vietnam, Netherland, Italy and China. UPL has subsidiaries across the world. The Company possesses a rich portfolio of more than 60 products; 20 were launched in the five years leading to 2011-12. FY12 was a landmark year in the history of the Company as it plugged the last major link in its global presence through acquisitions in Brazil, the fastest growing agrochemical market in the world and accounting for 15 percent of the global agricultural output. These acquisitions accounted for 9 percent of its revenues in FY12 and going ahead...
On June 4, 2010, the Union Finance Ministry came out with "Minimum Public Shareholding Guidelines", later (on August 9, 2010) revised. PSUs are expected to maintain a minimum public shareholding of 10 per cent within three years. For the private sector, this is 25 per cent. That means that promoters of listed entities bring down their stake to below 75% by June 3, 2013. Companies can do so either by diluting or de-listing. The most prominent candidates for the delisting will be MNC companies where...
